Ming Fai Enterprise International Co., Ltd

Safety Data Sheet according to OSHA HazCom Standard (2024) requirements

SDS No.: HKGH0327230604 Initial Date: 18/08/2025 Print Date: 18/08/2025

SECTION 1 Identification

Product name	Room spray-Woodland Harmony
Synonyms	Room spray-Woodland Harmony
Other means of identification	Not Available

Recommended use of the chemical and restrictions on use

Relevant identified uses	Room Spray
--------------------------	------------

Name, address, and telephone number of the chemical manufacturer, importer, or other responsible party

Registered company name	Ming Fai Enterprise International Co., Ltd		
Address	Unit D3, 8/F, TML Tower, No. 3 Hoi Shing Road, Tsuen Wan, New Territories, Hong Kong		
Telephone	852 2455 4888		
Fax	Not Available		
Website	Not Available		
Email	scarlett.chen@mingfaigroup.com		

Emergency phone number

Association / Organisation	ALDI, BATAVIA, IL 60510
Emergency telephone number(s)	Not Available
Other emergency telephone number(s)	Not Available

SECTION 2 Hazard(s) identification

Classification of the substance or mixture

Classification Hazardous to the aquatic environment — Chronic Hazard, Category 3

Label elements

Hazard pictogram(s)	Not Applicable	
Signal word	Not Applicable	

Hazard statement(s)

H412 Harmful to aquatic life with long lasting effects.

Hazard(s) not otherwise classified

Not Applicable

Precautionary statement(s) General

Not Applicable

Precautionary statement(s) Prevention

P273 Avoid release to the environment.

Precautionary statement(s) Response

Not Applicable

Precautionary statement(s) Storage

Not Applicable

Precautionary statement(s) Disposal

P501 Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
7732-18-5	80-90	<u>water</u>
61788-85-0	1-5	castor oil, hydrogenated, ethoxylated
6132-04-3	1-5	sodium citrate
9005-64-5	1-5	sorbitan monolaurate, ethoxylated
Not Applicable	1-2	Fragrance – AS288571
122-99-6	0.5-0.9	ethylene glycol phenyl ether
54464-57-2	0.5-0.9	isocyclemone E (as part of fragrance)
77-92-9	0.1-0.5	citric acid
70445-33-9	0.05-0.1	<u>ethylhexylglycerin</u>
10191-41-0	≤0.0001	alpha-tocopherol

The specific chemical identity and/or exact percentage (concentration) of fragrance composition has been withheld as a trade secret.

SECTION 4 First-aid measures

Description of first aid measures

Eye Contact	If this product comes in contact with eyes: • Wash out immediately with water. • If irritation continues, seek medical attention. • Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.		
Skin Contact	Wash hands after use.		
Inhalation	Other measures are usually unnecessary.		
Ingestion Immediately give a glass of water. First aid is not generally required. If in doubt, contact a Poisons Information Centre or a doctor.			

Most important symptoms and effects, both acute and delayed

See Section 11

Indication of any immediate medical attention and special treatment needed

May emit acrid smoke.

Combustion products include: carbon dioxide (CO2)

May emit poisonous fumes. May emit corrosive fumes.

Mists containing combustible materials may be explosive.

other pyrolysis products typical of burning organic material.

Treat symptomatically.

SECTION 5 Fire-fighting measures

Extinguishing media

The product contains a substantial proportion of water, therefore there are no restrictions on the type of extinguishing media which may be used. Choice of extinguishing media should take into account surrounding areas.

Though the material is non-combustible, evaporation of water from the mixture, caused by the heat of nearby fire, may produce floating layers of combustible substances. In such an event consider:

- ∙ foam.
- · dry chemical powder.
- · carbon dioxide.

Special hazards arising from the substrate or mixture

Fire Incompatibility	None known.		
Special protective equipment and precautions for fire-fighters			
 Alert Fire Brigade and tell them location and nature of hazard. Wear full body protective clothing with breathing apparatus. Prevent, by any means available, spillage from entering drains or water course. Use water delivered as a fine spray to control fire and cool adjacent area. Avoid spraying water onto liquid pools. DO NOT approach containers suspected to be hot. Cool fire exposed containers with water spray from a protected location. 			
	▶ If safe to do so, remove containers from path of fire.		
	The emulsion is not combustible under normal conditions. However, it will break down under fire conditions and the hydrocarbon component will burn. ▶ Combustible.		
	 Slight fire hazard when exposed to heat or flame. 		
Fire/Explosion Hazard	 Heating may cause expansion or decomposition leading to violent rupture of containers. On combustion, may emit toxic fumes of carbon monoxide (CO). 		

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

▶ Remove all ignition sources. ▶ Clean up all spills immediately. Minor Spills Avoid breathing vapours and contact with skin and eyes. ▶ Control personal contact with the substance, by using protective equipment. ▶ Contain and absorb spill with sand, earth, inert material or vermiculite. Place in a suitable, labelled container for waste disposal. Moderate hazard. ▶ Clear area of personnel and move upwind. Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves. Prevent, by any means available, spillage from entering drains or water course. Major Spills ▶ No smoking, naked lights or ignition sources. Increase ventilation. Stop leak if safe to do so. ▶ Contain spill with sand, earth or vermiculite. ▶ Collect recoverable product into labelled containers for recycling. Absorb remaining product with sand, earth or vermiculite. ▶ Collect solid residues and seal in labelled drums for disposal. · Wash area and prevent runoff into drains. If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling

Safe handling	Avoid contact with incompatible materials.
	→ When handling, DO NOT eat, drink or smoke.
	 Keep containers securely sealed when not in use.
	Always wash hands with soap and water after handling.
	→ Use good occupational work practice.
	Observe manufacturer's storage and handling recommendations contained within this SDS.
	Store in original containers.
	› Keep containers securely sealed.
Other information	> Store in a cool, dry, well-ventilated area.
	Store away from incompatible materials and foodstuff containers.
	Protect containers against physical damage and check regularly for leaks.
	 Observe manufacturer's storage and handling recommendations contained within this SDS.

Conditions for safe storage, including any incompatibilities

•		
Suitable container	Glass container is suitable for laboratory quantities Metal can or drum Packaging as recommended by manufacturer. Check all containers are clearly labelled and free from leaks.	
Storage incompatibility	None known	

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

| INGREDIENT DATA

Not Available

Emergency Limits

Ingredient	TEEL-1	TEEL-2	TEEL-3
sodium citrate	9.3 mg/m3	100 mg/m3	610 mg/m3
ethylene glycol phenyl ether	1.5 ppm	16 ppm	97 ppm

Ingredient	Original IDLH	Revised IDLH
water	Not Available	Not Available
castor oil, hydrogenated, ethoxylated	Not Available	Not Available
sodium citrate	Not Available	Not Available
sorbitan monolaurate, ethoxylated	Not Available	Not Available
ethylene glycol phenyl ether	Not Available	Not Available
citric acid	Not Available	Not Available
ethylhexylglycerin	Not Available	Not Available
alpha-tocopherol	Not Available	Not Available
isocyclemone E	Not Available	Not Available

Exposure controls

Enclosed local exhaust ventilation is required at points of dust, fume or vapour generation

HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapours. Barrier protection or laminar flow cabinets should be considered for laboratory scale handling.

A fume hood or vented balance enclosure is recommended for weighing/ transferring quantities exceeding 500 mg. When handling quantities up to 500 gram in either a standard laboratory with general dilution ventilation (e.g. 6-12 air changes per hour) is preferred. Quantities up to 1 kilogram may require a designated laboratory using fume hood, biological safety cabinet, or approved vented enclosures. Quantities exceeding 1 kilogram should be handled in a designated laboratory or containment laboratory using appropriate barrier/ containment technology.

Manufacturing and pilot plant operations require barrier/ containment and direct coupling technologies.

Barrier/ containment technology and direct coupling (totally enclosed processes that create a barrier between the equipment and the room) typically use double or split butterfly valves and hybrid unidirectional airflow/ local exhaust ventilation solutions (e.g. powder containment booths). Glove bags, isolator glove box systems are optional. HEPA filtration of exhaust from dry product handling areas is required. Fume-hoods and other open-face containment devices are acceptable when face velocities of at least 1 m/s (200 feet/minute) are achieved. Partitions, barriers, and other partial containment technologies are required to prevent migration of the material to uncontrolled areas. For non-routine emergencies maximum local and general exhaust are necessary. Air contaminants generated in the workplace possess varying escape' velocities which, in turn, determine the 'capture velocities' of fresh circulating air required to effectively remove the contaminant

Appropriate engineering controls

Type of Contaminant:	Air Speed:
solvent, vapours, etc. evaporating from tank (in still air)	0.25-0.5 m/s (50-100 f/min.)
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)
direct spray, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min.)

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be

a minimum of 1-2.5 m/s (200-500 f/min.) for extraction of gases discharged 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

The need for respiratory protection should also be assessed where incidental or accidental exposure is anticipated: Dependent on levels of contamination, PAPR, full face air purifying devices with P2 or P3 filters or air supplied respirators should be evaluated

The following protective devices are recommended where exposures exceed the recommended exposure control guidelines by factors of 10; high efficiency particulate (HEPA) filters or cartridges

10-25; loose-fitting (Tyvek or helmet type) HEPA powered-air purifying respirator.

25-50; a full face-piece negative pressure respirator with HEPA filters

50-100; tight-fitting, full face-piece HEPA PAPR

100-1000; a hood-shroud HEPA PAPR or full face-piece supplied air respirator operated in pressure demand or other positive pressure mode

Individual protection measures, such as personal protective equipment

See below

When handling very small quantities of the material eye protection may not be required. For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs:

- ▶ Chemical goggles. [AS/NZS 1337.1, EN166 or national equivalent]
- Face shield. Full face shield may be required for supplementary but never for primary protection of eyes

Eye and face protection

Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly.

Skin protection

See Hand protection below

NOTE:

- The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact.
- Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed

The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.

The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final choice.

Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include:

- frequency and duration of contact,
- chemical resistance of glove material,
- glove thickness and
- dexterity

Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent).

When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.

When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.

Some glove polymer types are less affected by movement and this should be taken into account when considering gloves for long-term

Contaminated gloves should be replaced. Hands/feet protection

As defined in ASTM F-739-96 in any application, gloves are rated as: · Excellent when breakthrough time > 480 min

- Good when breakthrough time > 20 min
- Fair when breakthrough time < 20 min
- Poor when glove material degrades

For general applications, gloves with a thickness typically greater than 0.35 mm, are recommended.

It should be emphasised that glove thickness is not necessarily a good predictor of glove resistance to a specific chemical, as the permeation efficiency of the glove will be dependent on the exact composition of the glove material. Therefore, glove selection should also be based on consideration of the task requirements and knowledge of breakthrough times.

Glove thickness may also vary depending on the glove manufacturer, the glove type and the glove model. Therefore, the manufacturers technical data should always be taken into account to ensure selection of the most appropriate glove for the task

Note: Depending on the activity being conducted, gloves of varying thickness may be required for specific tasks. For example:

Thinner gloves (down to 0.1 mm or less) may be required where a high degree of manual dexterity is needed. However, these gloves are only likely to give short duration protection and would normally be just for single use applications, then disposed of.

Thicker gloves (up to 3 mm or more) may be required where there is a mechanical (as well as a chemical) risk i.e. where there is abrasion or puncture potential

Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended

- ▶ Rubber gloves (nitrile or low-protein, powder-free latex, latex/ nitrile). Employees allergic to latex gloves should use nitrile gloves in preference.
- Double gloving should be considered.
- ▶ PVC gloves.
- ▶ Change gloves frequently and when contaminated, punctured or torn.
- Wash hands immediately after removing gloves.
- ▶ Protective shoe covers. [AS/NZS 2210]
- Head covering.

Body protection

Other protection

See Other protection below

For quantities up to 500 grams a laboratory coat may be suitable.

- For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar
- For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers.
- · For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.
- · Eye wash unit.
- ▶ Ensure there is ready access to an emergency shower. ▶ For Emergencies: Vinyl suit

Recommended material(s)

GLOVE SELECTION INDEX

Not Available

Glove selection is based on a modified presentation of the: Forsberg Clothing Performance Index'.

Type A-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001. ANSI Z88 or national equivalent)

Selection of the Class and Type of respirator will depend upon the level of breathing zone contaminant and the chemical nature of the contaminant. Protection Factors (defined as the ratio of contaminant outside and inside the mask) may also be important.

Required minimum protection factor	Maximum gas/vapour concentration present in air p.p.m. (by volume)	Half-face Respirator	Full-Face Respirator
up to 10	1000	A-AUS / Class1 P2	-
up to 50	1000	-	A-AUS / Class 1 P2
up to 50	5000	Airline *	-
up to 100	5000	-	A-2 P2
up to 100	10000	-	A-3 P2
100+			Airline**

* - Continuous Flow ** - Continuous-flow or positive pressure demand A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
 The wearer must be warned to leave the contaminated area immediately on
- The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
- Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

SECTION 9 Physical and chemical properties

Appearance	self-color		
Physical state	Liquid	Relative density (Water = 1)	Not Available
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	5.84	Decomposition temperature (°C)	Not Available
Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Available
Flash point (°C)	>65.6	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Available	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Available	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available
Solubility in water	Not Available	pH as a solution (1%)	Not Available
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available
Heat of Combustion (kJ/g)	Not Available	Ignition Distance (cm)	Not Available
Flame Height (cm)	Not Available	Flame Duration (s)	Not Available
Enclosed Space Ignition Time Equivalent (s/m3)	Not Available	Enclosed Space Ignition Deflagration Density (g/m3)	Not Available
Nanoform Solubility	Not Available	Nanoform Particle Characteristics	Not Available
Particle Size	Not Available		

SECTION 10 Stability and reactivity

Reactivity	See section 7
Chemical stability	 Unstable in the presence of incompatible materials. Product is considered stable. Hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 Toxicological information

Information on toxicological effects

Inhaled	The material is not thought to produce adverse health e that exposure be kept to a minimum and that suitable cont		· · · · · · · · · · · · · · · · · · ·	theless, good hygiene practice requires			
Ingestion	The material has NOT been classified other classification evidence.	systems as "har	mful by ingestion". This is becau	use of the lack of corroborating animal or human			
Skin Contact	The material is not thought to produce adverse health effort exposure be kept to a minimum and that suitable gloves to		•	less, good hygiene practice requires that			
Еуе	Although the liquid is not thought to be an irritant, direct conjunctival redness (as with windburn).	ontact with the e	eye may produce transient disco	omfort characterised by tearing or			
Chronic	Long-term exposure to the product is not thought to prominimised as a matter of course.	oduce chronic e	ffects adverse to the health; nev	ertheless exposure by all routes should be			
	TOXICITY		IRRITATION				
Room spray-Woodland							
Harmony	Not Available		Not Available				
	TOXICITY		IRRITATION				
water	Oral (Rat) LD50: >90000 mg/kg			Not Available			
	TOXICITY	IRRITATION					
castor oil, hydrogenated,	Oral (Rat) LD50: >2000 mg/kg Eye: no adverse effect observed (not irritating)						
ethoxylated	Skin: no adverse effect observed (not irritating)						
	Similing advance officer observed (not findung)						
	TOXICITY	IRRITATION					
	dermal (rat) LD50: >2000 mg/kg	Eye	e: no adverse effect observed	(not irritating)			
sodium citrate	Oral (Mouse) LD50; 5000-6000 mg/kg	Ski	n: no adverse effect observed	adverse effect observed (not irritating)			
	TOXICITY	ı	RRITATION				
	Dermal (Guinea Pig) LD50: >3000 mg/kg		Eye: no adverse effect observe	ed (not irritating)			
sorbitan monolaurate, ethoxylated	Inhalation (Rat) LC50: >5.1 mg/l4h		Skin (Human): 15mg/3D (intermittent) - Mild				
	Oral (Mouse) LD50; >33000 mg/kg		Skin: no adverse effect observ	ed (not irritating)			
	TOXICITY	IRRITATIO	N				
	dermal (rat) LD50: >2000 mg/kg	Eye (Roder	nt - rabbit): 250ug/24H - Sever	е			
	Oral (Rat) LD50: 1260 mg/kg	Eye (Roder	nt - rabbit): 6mg - Moderate				
ethylene glycol phenyl ether		Eye: adver	se effect observed (irreversible	damage)			
		Eye: adver	se effect observed (irritating)				
		Skin (Rode	nt - rabbit): 500mg/24H - Mild				
		Skin: adver	se effect observed (irritating)				
		Skin: no ad	verse effect observed (not irrit	ating)			

	TOXICITY	IRR	TATION		
	dermal (rat) LD50: >2000 mg/kg	Eye (Rodent - rabbit): 750ug/24H - Sev		evere	
	Oral (Rat) LD50: 3000 mg/kg	Eye: adverse effect observed (irritating)		1)	
citric acid		Skin (Rodent - rabbit): 0.5mL - Moderate			
		Skin	(Rodent - rabbit): 500mg/24H - N	1ild	
		Skin	: adverse effect observed (irritating	g)	
		Skin	: no adverse effect observed (not	irritating)	
	TOXICITY		IRRITATION		
			Skin (Human - woman): 5%/2D	:in (Human - woman): 5%/2D	
ethylhexylglycerin	Inhalation (Rat) LC50: 2.83 mg/l4h		Skin (Human - woman): 5%/2D (intermittent)		
	Oral (Rat) LD50: >2000 mg/kg				
	TOXICITY	IDI	RITATION		
aluba ta aaubayal	dermal (rat) LD50: >3000 mg/kg		Eye: no adverse effect observed (not irritating)		
alpha-tocopherol			in: no adverse effect observed (no	· •	
	TOXICITY			IRRITATION	

WATER

No significant acute toxicological data identified in literature search.

CASTOR OIL, HYDROGENATED, ETHOXYLATED

Inhalation-risk test (IRT): No mortality within 8 hours as shown in animal studies. The inhalation of a highly saturated vapor-air mixture represents no acute hazard. Skin irritation: rabbit: non-irritant (OECD Guideline 404) Eye irritation: rabbit: non-irritant (BASF-Test) Sensitization: Guinea pig maximization test/guinea pig: Non-sensitizing. Chronic toxicity Genetic toxicity: In the majority of studies performed with microorganisms and in mammalian cell culture, a mutagenic effect was not found. A mutagenic effect was also not observed in in vivo tests. Developmental toxicity/teratogenicity: No indications of a developmental toxic / teratogenic effect were seen in animal studies. * BASF MSDS Cremaphor RH Surfactant

This product contains partially hydrogenated fatty acids and/ or trans fatty acids.

The consumption of trans fats increases the risk of coronary heart disease by raising levels of LDL cholesterol and lowering levels of 'good' HDL cholesterol. There is an ongoing debate about a possible differentiation between trans fats of natural origin and trans fats of man-made origin but so far no scientific consensus has been found. Two Canadian studies have shown that the natural trans fat vaccenic acid, found in beef and dairy products, may have an opposite health effect and could actually be beneficial compared to hydrogenated vegetable shortening, or a mixture of pork lard and soy fat, by lowering total and LDL cholesterol and triglyceride levels. In lack of recognized evidence and scientific agreement, nutritional authorities consider all trans fats as equally harmful for health and recommend that consumption of trans fats be reduced to trace amounts.

The use of hydrogenated oils in foods has never been completely satisfactory. Because the center arm of the triglyceride is shielded somewhat by the end fatty acids, most of the hydrogenation occurs on the end fatty acids,

While full hydrogenation produces largely saturated fatty acids, partial hydrogenation results in the transformation of unsaturated cis fatty acids to trans fatty acids in the oil mixture due to the heat used in hydrogenation. Partially hydrogenated oils and their trans fats have increasingly been viewed as 'unhealthy'.

Trans fat is the common name for unsaturated fat with trans-isomer (E-isomer) fatty acid(s). Because the term refers to the configuration of a double carbon-carbon bond, trans fats are sometimes monounsaturated or polyunsaturated, but never saturated. Trans fats do exist in nature but also occur during the processing of polyunsaturated fatty acids in food production. Trans fats occur naturally in a limited number of cases: vaccenyl and conjugated linoleyl (CLA) containing trans fats occur naturally in trace amounts in meat and dairy products from ruminants

The exact biochemical methods by which trans fats produce specific health problems are a topic of continuing research. One theory is that the human lipase enzyme works only on the cis configuration and cannot metabolise a trans fat. A lipase is a water-soluble enzyme that helps digest, transport, and process dietary lipids such as triglycerides, fats, and oils in most - if not all - living organisms. While the mechanisms through which trans fats contribute to coronary heart disease are fairly well understood, the mechanism for trans fat's effect on diabetes is still under investigation. Trans fatty acids may impair the metabolism of long-chain polyunsaturated fatty acids (LCPUFAs), but

maternal pregnancy trans fatty acid intake has been inversely associated with LCPUFAs levels in infants at birth thought to underlie the positive association between breastfeeding and intelligence.

There are suggestions that the negative consequences of trans fat consumption go beyond the cardiovascular risk. In general, there is much less scientific consensus asserting that eating trans fat specifically increases the risk of other chronic health problems:

It has been suggested that the intake of both trans fats and saturated fats promote the development of Alzheimer disease, although not confirmed in an animal model. It has been found that trans fats impaired memory and learning in middle-age rats. The rats' brains of trans-fat eaters had fewer proteins critical to healthy neurological function. Inflammation in and around the hippocampus, the part of the brain responsible for learning and memory. These are the exact types of changes normally seen at the onset of Alzheimer's, but seen after six weeks, even though the rats were still young.

There is a growing concern that the risk of type 2 diabetes increases with trans fat consumption. [52] However, consensus has not been reached. For example, one study found that risk is higher for those in the highest quartile of trans fat consumption. Another study has found no diabetes risk once other factors such as total fat intake and BMI were accounted for.

Research indicates that trans fat may increase weight gain and abdominal fat, despite a similar caloric intake. A 6-year experiment revealed that monkeys fed a trans fat diet gained 7.2% of their body weight, as compared to 1.8% for monkeys on a mono-unsaturated fat diet. Although obesity is frequently linked to trans fat in the popular media, this is generally in the context of eating too many calories; there is not a strong scientific consensus connecting trans fat and obesity, although the 6-year experiment did find such a link, concluding that 'under controlled feeding conditions, long-term TFA consumption was an independent factor in weight gain. TFAs enhanced intra-abdominal deposition of fat, even in the absence of caloric excess, and were associated with insulin resistance, with evidence that there is impaired post-insulin receptor binding signal transduction.

Liver Dysfunction: Trans fats are metabolised differently by the liver than other fats and interfere with delta 6 desaturase. Delta 6 desaturase is an enzyme involved in converting essential fatty acids to arachidonic acid and prostaglandins, both of which are important to the functioning of cells.

Infertility in women: One 2007 study found, 'Each 2% increase in the intake of energy from trans unsaturated fats, as opposed to that from carbohydrates, was associated with a 73% greater risk of ovulatory infertility...'.

Major depressive disorder: Spanish researchers analysed the diets of 12,059 people over six years and found those who ate the most trans fats had a 48 per cent higher risk of depression than those who did not eat trans fats. One mechanism may be trans-fats' substitution for docosahexaenoic acid (DHA) levels in the orbitofrontal cortex (OFC). Very high intake of trans-fatty acids (43% of total fat) in mice from 2 to 16 months of age was associated with lowered DHA levels in the brain (p=0.001) When the brains of 15 major depressive subjects who had committed suicide were examined post-mortem and compared against 27 age-matched controls, the suicidal brains were found to have 16% less (male average) to 32% (female average) less DHA in the OFC. The OFC is known to control reward, reward expectation and empathy, which are all negatively impacted in depressive mood disorders, as well as regulating the limbic system>

SORBITAN MONOLAURATE, ETHOXYLATED

The Cosmetic Ingredient Review (CIR) Expert Panel concluded that listed polysorbates are safe in cosmetics when formulated to be non-irritating. This conclusion supersedes the conclusion reached in the 1984, 2000, and 2001 CIR safety assessments. This safety assessment combines polysorbates reviewed in 3 previous safety assessments with other polysorbates that have not been reviewed by the CIR Panel into a group of 80 polyethoxylated sorbitan or sorbitol esters of fatty acid.

Following oral administration of polysorbate 20 to rats, ester bonds of polysorbates are hydrolyzed within the digestive tract by pancreatic lipase.24 Free fatty acids were absorbed from the digestive tract and oxidized and excreted,

mainly as carbon dioxide in exhaled breath. No migration of the polyoxyethylene sorbitan into the thymus lymph nodes has been demonstrated. No sex difference has been detected in the disposition of polysorbates in rats. Following oral ingestion of polysorbate 20 in humans, 90% or more of the administered substance was excreted in the feces as metabolites, with the polyoxyethylene sorbitan structure maintained, and 2%-3% of these metabolites were excreted in the urine

The Panel considered the data available to characterize the potential for polysorbates to cause systemic toxicity, irritation, sensitization, reproductive and developmental toxicity, and genotoxicity. They noted the lack of systemic toxicity at low and moderate doses in several acute and repeated-dose oral exposure studies, and low toxicity at high doses; little or no irritation or sensitization in multiple tests of dermal and ocular exposure; the absence of genotoxicity in multiple Ames tests and chromosome aberration tests, and minimal irritation and lack of sensitization in tests of dermal exposure at concentration of use. The Panel recognizes that there are data gaps regarding use and concentration of these ingredients. However, the overall information available on the types of products in which these ingredients are used, concentrations of use and the similar pattern of use raise no safety concerns. The Panel note that polysorbate 20, polysorbate 65, and polysorbate 80 were shown to enhance dermal drug absorption. The Panel cautions that care should be taken in formulating cosmetic products that may contain these ingredients in combination

with any ingredients whose safety was based on their lack of dermal absorption, or when dermal absorption was a concern. Especially, care should be taken when creating formulations intended for use on infants.

To address the possible presence of 1,4-dioxane and ethylene oxide impurities in these ingredients, the Panel stressed that the cosmetics industry should continue to use the necessary procedures to limit these impurities from the PEG ingredients

before blending them into cosmetic formulations. The Panel expressed concern about pesticide residues and heavy metals that may be present in botanical (ie, coconut-derived) ingredients. They stressed that the cosmetics industry should continue to use current good manufacturing practices (cGMPs) to limit impurities. Data from the 1984 safety assessment suggested that polysorbates caused a slight enhancement of tumor development caused by 7,12-dimethyl-benz[a]anthracene (DMBA) and N-methyl-N -nitro-N-nitrosoguanidine (MNNG); however, the data were not consistent. For other compounds, the tumorigenic properties of 3-methyl-cholanthrene (MCA) and 3,4-benz[a]pyrene (BP) were not enhanced by polysorbates. Since the tumor enhancement effects were inconsistent and depended on the simultaneous exposure to strong chemical carcinogens, which are not present in cosmetics, the Panel felt that the weak tumor enhancement effects were not relevant to cosmetic formulations. Because some studies showed minimal irritation at concentrations that are used in cosmetics, the Panel cautioned that products containing these ingredients should be formulated to be non-irritating. It was noted that at the time of the 2001 safety assessment on sorbeth beeswaxes, the Panel had recommended that

cosmetic formulations containing PEGs not be used on damaged skin because of the possibility of renal toxicity when PEGs were applied to severely damaged skin, such as in burn patients. Since then, PEGs have been re-reviewed and the additional data demonstrated minimal dermal penetration of low-molecular weight PEGs. The amount of PEGs that would penetrate the stratum corneum barrier, even if damaged, from the use of cosmetics was well below the level of renal toxicity. Therefore, the Panel has removed the caveat that PEGs should not be used on damaged skin. The Panel strongly asserted that it is inappropriate to apply cosmetic products containing high concentrations of PEGs to individuals exhibiting barrier skin disruption through both the stratum corneum and the epidermis.

The Panel discussed the issue of incidental inhalation exposure from spray products, including aerosol and pump hair sprays, spray deodorants, spray body and hand products, and spray moisturizing products. The limited acute exposure

data available from 1 new inhalation study and 1 historical tracheal study suggest little potential for respiratory effects at relevant doses. These ingredients are reportedly used at concentrations up to 4% in cosmetic products that may be aerosolized. The Panel noted that 95%-99% of droplets/particles would not be respirable to any appreciable amount.

Coupled with the small actual exposure in the breathing zone and the concentrations at which the ingredients are used, the available information indicates that incidental inhalation would not be a significant route of exposure that might lead to local respiratory or systemic effects.

Safety Assessment of Polysorbates as Used in CosmeticJuly 2015

https://www.cir-safety.org/sites/default/files/PSorba_062015_FR_0.pdf

For sorbitan esters, ethoxylated (syn: polyoxyethylene sorbitan esters):

Some of the early short-term studies with these polyoxyethylene sorbitan esters in rats and hamsters showed deleterious effects. Subsequent work suggests that these were largely due to diarnhoea resulting from a large amount of unabsorbed polyglycol, possibly aggravated in some experiments by the use of an unsuitable basal diet. Since that time there has been considerable improvement in testing procedures, and more extensive long-term studies have been carried out. It seems reasonable therefore to base the evaluation of these substances on the levels causing no adverse effects indicated by the results of the more recent investigations.

The significance of the local tumours which were produced by injection has been discussed at the meeting of the Scientific Group (1966). No increase in tumour incidence has followed the oral intake of polyoxyethylene sorbitan esters. Furthermore, large doses of the oleate and stearate have been well tolerated by human subjects.

Polyoxyethylene (20) sorbitan monoester of lauric, oleic, palmitic and stearic acid and triester of stearic acid Seventeenth Report of the Joint FAO/WHO Expert Committee on Food Additives, Wld Hlth Org. Techn. Rep. Ser., 1974, No. 539; FAO Nutrition Meetings Report Series, 1974, No. 53.

	The sorbitan esters are agents that typically find use as emulsifiers, stabilizers, and thickeners in foods, cosmetics and medical products. They do not represent a toxicological concern since they are derived from naturally occurring materials and are ultimately metabolised back to these same natural constituents.
ETHYLENE GLYCOL PHENYL ETHER	Bacterial cell mutagen The material may produce severe irritation to the eye causing pronounced inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis. The aryl alkyl alcohol (AAA) fragrance ingredients have diverse chemical structures, with similar metabolic and toxicity profiles. The AAA fragrances demonstrate low acute and subchronic toxicity by skin contact and swallowing. At concentrations likely to be encountered by consumers, AAA fragrance ingredients are non-irritating to the skin. The potential for eye irritation is minimal. With the exception of benzyl alcohol, phenethyl and 2-phenoxyethyl AAA alcohols, testing in humans indicate that AAA fragrance ingredients generally have no or low sensitization potential. Available data indicate that the potential for photosensitization is low. Testing suggests that at current human exposure levels, this group of chemicals does not cause maternal or developmental toxicity. Animal testing shows no cancer-causing evidence, with little or no genetic toxicity. It has been concluded that these materials would not present a safety concern at current levels of use, as fragrance ingredients.
CITRIC ACID	Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production.
ETHYLHEXYLGLYCERIN	Oral (-) LDS0: 2000 mg/kg OECD 40). Skin: non-initiant OECD 440 Bermar (-) LDS0: 2000 mg/kg OECD 40). Eye: initiant OECD 440 Shortsensitising OECD 46)? The notion effect level for oral application to ratio serve 34 kays is 100 mg/kg/day. A NOEL cannot be determined. OECD 467 No experimental information on genotoxicity in vitro or in vivo available. *Schulke 400 control of the co
ALPHA-TOCOPHEROL	[ROCHE] * Bronson and Jacobs SDS (for similar products) Use in foodstuffs is consistent with low order of toxicity. Based on laboratory and animal testing, exposure to the material may result in irreversible effects and mutations in humans. alpha-Tocopherol was non-mutagenic and non-carcinogenic, and the results of reproduction/ teratology studies did not indicate that alpha-tocopherol had adverse effects on reproductive function. However, in a long-term study in rats, a no-effect level could not be established with respect to effects on blood clotting and liver histology, and there was evidence from human studies that excessive intakes of alpha-tocopherol could cause haemorrhage. Other adverse effects noted in clinical studies at doses of > 720 mg alpha-tocopherol/day included weakness, fatigue, creatinuria and effects on steroid hormone metabolism. Clinical studies indicate that, generally, intakes of below about 720 mg/day are without adverse effects in man, but one investigation in elderly patients showed an increase in serum cholesterol at doses of 300 mg alpha-tocopherol daily. Incidences of allergic reactions seem to be very rare. alpha-Tocopherol may be an essential nutrient. The U.S. National Academy of Sciences/National Research Council has recommended a dietary allowance of 0.15 mg/kg b.w./day. However, excessive intakes of alpha-tocopherol produce adverse clinical and biochemical effects, and self-medication with large doses of vitamin E preparations could present a hazard.

The previously-allocated ADI was amended to include a lower value, which reflects the fact that alpha-tocopherol may be an essential nutrient. The upper value, which represents the maximum value for the AID, is based on clinical experience in man. IPCS Inchem: https://www.inchem.org/documents/jecfa/jecmono/v21je05.htm Dermal (Rat) LD50: >5000 mg/kg(OECD 402)* Eye: non-irritant * (QSAR) * Sensitisation: Component: 68155-66-8 LLNA mouse: Result: Causes sensitization. Method: OECD 429 Repeated dose toxicity: Component: 68155-66-8 Oral rat Number of exposures: 1x /day NOEL: 150 mg/kg Method: OECD Test Guideline 407 Remarks: Repeated dose (28 days) toxicity (oral) Teratogenicity: Component: 68155-66-8 Application Route: Oral rat Number of exposures: 1x /day *IFF MSDS The substance is an individual isomer of the fragrance ingredient OTNE [predominant isomer: 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8tetramethyl-2-naphthyl)ethan-1- one; synonyms - tetramethylacetyloctahydronaphthalene, Iso-E Super; other isomers: 1-(1,2,3,4,5,6,7,8-1) octahydro 2,3,8,8,-tetramethyl-2-naphthyl)ethan-1-one, and 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-aceto naphthalenone]. A synthetic terpenoid considered to be a petroleum-derived aroma chemical No data were available regarding chemical disposition, metabolism, or toxicokinetics; acute, short term, subchronic, or chronic toxicity; synergistic or antagonistic activity; reproductive or teratological effects; carcinogenicity; genotoxicity; or immunotoxicity of OTNE Several compounds were considered as structural analogues of OTNE. Data are provided for the tetralin derivatives AHTN (CAS RN: 21145-77-7; Tonalide, 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8 hexamethyl-2-naphthalenyl)ethanone) and AETT, (*CAS RN: 88-29-9; Versalide, 1-(3-ethyl-5,6,7,8-tetrahydro-5,5,8,8 tetramethyl-2-naphthalenyl)ethanone) which are also polycyclic synthetic musks. Both compounds have been detected in human adipose tissue and human milk. In one rat study, AHTN produced acute hepatic damage but in another had no adverse effects when administered to lactating rats beginning the third week of pregnancy at doses producing levels in the milk ~1000 times those reported in human milk. Administered by gavage at 50 mg/kg/day on gestation days 7 through 17, AHTN produced clinical signs and reduced weight gain and feed consumption in dams but had no adverse effect on embryo-fetal viability, growth, or morphology. In female rats, AETT induced classic degenerative changes in the liver and effects on the nucleolus and was neurotoxic. Effects included demyelination, hyperirritability, limb weakness, and gait abnormality that became severe ataxia. AHTN gave negative results in several genotoxicity studies (e.g., the Salmonella typhimurium/Escherichia coli plate incorporation and liquid preincubation assays and in vivo mouse micronucleus assays) . Human Data is available ISO-E super (CAS RN: 54464-57-2): In dermatological patients, two cases of an allergic reaction towards Iso-E Super were observed on day 3 or 4 of application (patch test); however, this was not proved to be clinically relevant ISOCYCLEMONE E Chronic exposure may result in permanent hypersensitivity] In a study with female mice, Iso E Super was positive in the local lymph node assay (LLNA) and irritancy assay (IRR), but negative in the mouse ear swelling test (MEST). Fragrance allergens act as haptens, which are small molecules that cause an immune reaction only when attached to a carrier protein. However, not all sensitizing fragrance chemicals are directly reactive, but some require previous activation. A prehapten is a chemical that itself causes little or no sensitization, but it is transformed into a hapten outside the skin by a chemical reaction (oxidation in air or reaction with light) without the requirement of an enzyme. For prehaptens, it is possible to prevent activation outside the body to a certain extent by different measures, for example, prevention of air exposure during handling and storage of the ingredients and the final product, and by the addition of suitable antioxidants. When antioxidants are used, care should be taken that they will not be activated themselves, and thereby form new sensitisers. Prehaptens: Most terpenes with oxidisable allylic positions can be expected to self-oxidise on air exposure. Depending on the stability of the oxidation products that are formed, the oxidized products will have differing levels of sensitization potential. Tests shows that air exposure of lavender oil increased the potential for sensitization. Prohaptens: Compounds that are bioactivated in the skin and thereby form haptens are referred to prohaptens. The possibility of a prohapten being activated cannot be avoided by outside measures. Activation processes increase the risk for cross-reactivity between fragrance substances. Various enzymes play roles in both activating and deactivating prohaptens. Skin-sensitizing prohaptens can be recognized and grouped into chemical classes based on knowledge of xenobiotic bioactivation reactions, clinical observations and/or studies of sensitization. QSAR prediction: Prediction of sensitization activity of these substances is complex, especially for those substances that can act both as pre- and prohaptens. The alkyl cyclic ketone (ACK) fragrance ingredients are a diverse group of structures with similar metabolic and toxicity profiles. ACK fragrance materials have low acute toxicity. Repeated exposure causes some adverse effects in biochemical tests and blood cell counts. They are not considered to be irritating to the skin of humans. In animals, mild to moderate eye irritation was seen; however, full recovery usually occurred. Human studies showed that ACK fragrance ingredients have low potential for sensitization. Phototoxicity and photosensitization were not demonstrated in humans. Developmental toxicity occurred only when toxicity also appeared in the mother. Tests showed that this group of substances did not cause genetic toxicity. CASTOR OIL. Polyethers (such as ethoxylated surfactants and polyethylene glycols) are highly susceptible to being oxidized in the air. They then form HYDROGENATED, complex mixtures of oxidation products. ETHOXYLATED & SORBITAN Animal testing reveals that whole the pure, non-oxidised surfactant is non-sensitizing, many of the oxidation products are sensitisers. The MONOLAURATE. oxidization products also cause irritation. **ETHOXYLATED** For citric acid (and its inorganic citrate salts) **SODIUM CITRATE & CITRIC** Based on extensive animal testing data and on human experience, citric acid has low acute toxicity. Citric acid is not suspected of causing cancer, birth defects or reproductive toxicity. Further, it does not cause mutations. Also, the sensitizing potential is considered low. In contrast, irritation, particularly of the eyes but also the airways and the skin, is the main hazard presented by citric acid. SORBITAN MONOLAURATE. ETHOXYLATED & ETHYLENE The material may cause skin irritation after prolonged or repeated exposure and may produce on contact skin redness, swelling, the **GLYCOL PHENYL ETHER &** production of vesicles, scaling and thickening of the skin. CITRIC ACID

Acute Toxicity	×	Carcinogenicity	×
Skin Irritation/Corrosion	×	Reproductivity	×
Serious Eye Damage/Irritation	×	STOT - Single Exposure	×
Respiratory or Skin sensitisation	×	STOT - Repeated Exposure	×
Mutagenicity	×	Aspiration Hazard	×

I egend: ★ - Data either not available or does not fill the criteria for classification

SECTION 12 Ecological information

т	ox	i	ci	ť

xicity									
	Endpoint	Test Duration	(hr)	Species	Va	lue	Q	ource	
Room spray-Woodland Harmony	Not Available	Not Available	(1117)		Not Available Not Available				nle .
	Not Available	Not Available		NOT Availa	DIE NO	nt Available	14	Ot Availai	JIC .
	Endpoint	Test Duration	Test Duration (hr)		Va	lue	S	ource	
water	Not Available	Not Available	(···/	Species Not Availa		t Available		ot Availal	nle
	Not Available	Not Available		140t Availa	DIC 140	TAVAIIADIC	14	Ot Availai	JIG
	Endpoint	Test Duration (hr)		Species			Value		Source
	EC50	72h		Algae or other	aquatic plants		>1mg/l		2
castor oil, hydrogenated,	EC50	48h		Crustacea			>1mg/l		2
ethoxylated	EC50(ECx)	48h		Crustacea			>1mg/l		2
	LC50	96h		Fish			>1mg/l		2
	Endpoint	Test Duration (hr)	Speci	es		Value			Source
	EC50	48h	Crusta			>50mg/l			2
sodium citrate	EC50	96h		or other aquation	plants		32000mg/l		1
	EC50(ECx)	48h	Crusta		•	>50mg/l			2
						'			
sorbitan monolaurate,	Endpoint	Test Duration	(hr)		Species	Value		Source	:e
ethoxylated	LC50	96h			Fish	383mg/	1	2	
	Endpoint	Test Duration (hr)	Species			Value	Value	
	EC50	72h		Algae or other	aquatic plants		>100mg/l		2
thylene glycol phenyl ether	EC50	48h		Crustacea			460mg/l		2
	NOEC(ECx)	24h		Fish			5mg/l		2
	LC50	96h		Fish			154mg/l	154mg/l	
	Endpoint	Test Duration (hr)		Species			Value		Source
	EC50	72h		Algae or other a	quatic plants		990mg/l		2
citric acid	EC50	48h	(Crustacea			>50mg/l		2
	EC50(ECx)	48h	48h Crustacea				>50mg/l		2
	LC50	96h	ı	Fish			>100mg/l		2
	Endpoint	Test Duration (hr)		Species			Value		Source
	EC50	72h		Algae or other aquatic plants			48.28mg/l		2
ethylhexylglycerin	EC50	48h		Crustacea			78.3mg/l		2
	NOEC(ECx)	72h		Fish			<1.5mg/l		2
	LC50	96h		Fish			60.2mg/l		2
									_
	Endpoint	Test Duration (hr)		Species			Value		Source
-1-1-411	EC50	72h		Algae or other a	quatic plants		>25.8mg/l		2
alpha-tocopherol	EC50	48h		Crustacea			>23.53mg/l		2
	NOEC(ECx)	384h		Fish 			1mg/l		4
	LC50	96h		ish			>10mg/l		2
	Endneint	Toot Privation (b.)		Species			Value		Sauras
	Endpoint EC50	Test Duration (hr)		Species Algae or other a	aquatic plants	Value			Source 2
isocyclemone E	EC50	48h		Crustacea	aquatic piditis		>2.6mg/l 1.38mg/l		2
isocyclemone E	NOEC(ECx)	504h		Crustacea			0.028mg/l		2
							1.3mg/l	_	
	LC50	96h		Fish			⊥ L.5mg/l		2

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
water	LOW	LOW
ethylene glycol phenyl ether	LOW	LOW
citric acid	LOW	LOW
alpha-tocopherol	HIGH	HIGH

Bioaccumulative potential

Ingredient	Bioaccumulation
water	LOW (LogKOW = -1.38)
sodium citrate	LOW (LogKOW = -0.28)
sorbitan monolaurate, ethoxylated	LOW (LogKOW = -2.03)
ethylene glycol phenyl ether	LOW (LogKOW = 1.16)
citric acid	LOW (LogKOW = -1.64)
alpha-tocopherol	LOW (LogKOW = 12.18)
isocyclemone E	HIGH (LogKOW = 5.18)

Mobility in soil

•	
Ingredient	Mobility
ethylene glycol phenyl ether	LOW (Log KOC = 12.12)
citric acid	LOW (Log KOC = 10)
alpha-tocopherol	LOW (Log KOC = 51280000)

Other adverse effects

No evidence of ozone depleting properties were found in the current literature.

SECTION 13 Disposal considerations

Waste treatment methods

- Containers may still present a chemical hazard/ danger when empty.
- ▶ Return to supplier for reuse/ recycling if possible.

Otherwise:

- If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.
- ▶ Where possible retain label warnings and SDS and observe all notices pertaining to the product.

Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked.

A Hierarchy of Controls seems to be common - the user should investigate:

Product / Packaging disposal

- ▶ Reduction
- Reuse Recycling
- Disposal (if all else fails)

This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. If it has been contaminated, it may be possible to reclaim the product by filtration, distillation or some other means. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate.

- ▶ DO NOT allow wash water from cleaning or process equipment to enter drains.
- It may be necessary to collect all wash water for treatment before disposal.
- ▶ In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.
- ▶ Where in doubt contact the responsible authority.
- ▶ Recycle wherever possible or consult manufacturer for recycling options.
- Consult State Land Waste Authority for disposal.
- ▶ Bury or incinerate residue at an approved site.
- Recycle containers if possible, or dispose of in an authorised landfill.

SECTION 14 Transport information

Labels Required

Marine Pollutant

NO

Land transport (DOT): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

14.7. Maritime transport in bulk according to IMO instruments

14.7.1. Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

14.7.2. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

•		
Product name	Group	
water	Not Available	
castor oil, hydrogenated, ethoxylated	Not Available	
sodium citrate	Not Available	
sorbitan monolaurate, ethoxylated	Not Available	
ethylene glycol phenyl ether	Not Available	
citric acid	Not Available	
ethylhexylglycerin	Not Available	
alpha-tocopherol	Not Available	
isocyclemone E	Not Available	

14.7.3. Transport in bulk in accordance with the IGC Code

Product name	Ship Type
water	Not Available
castor oil, hydrogenated, ethoxylated	Not Available
sodium citrate	Not Available
sorbitan monolaurate, ethoxylated	Not Available
ethylene glycol phenyl ether	Not Available
citric acid	Not Available
ethylhexylglycerin	Not Available
alpha-tocopherol	Not Available
isocyclemone E	Not Available

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

water is found on the following regulatory lists

US Toxic Substances Control Act (TSCA) - Chemical Substance Inventory

castor oil, hydrogenated, ethoxylated is found on the following regulatory lists

US Toxic Substances Control Act (TSCA) - Chemical Substance Inventory

sodium citrate is found on the following regulatory lists

US DOE Temporary Emergency Exposure Limits (TEELs)

US Toxic Substances Control Act (TSCA) - Chemical Substance Inventory

sorbitan monolaurate, ethoxylated is found on the following regulatory lists

US Toxic Substances Control Act (TSCA) - Chemical Substance Inventory

ethylene glycol phenyl ether is found on the following regulatory lists

US - California Hazardous Air Pollutants Identified as Toxic Air Contaminants

US - Pennsylvania - Hazardous Substance List

 ${\tt US\ DOE\ Temporary\ Emergency\ Exposure\ Limits\ (TEELs)}$

US EPCRA Section 313 Chemical List

US New York City Community Right-to-Know: List of Hazardous Substances

US Toxic Substances Control Act (TSCA) - Chemical Substance Inventory

citric acid is found on the following regulatory lists

US Toxic Substances Control Act (TSCA) - Chemical Substance Inventory

ethylhexylglycerin is found on the following regulatory lists

Not Applicable

alpha-tocopherol is found on the following regulatory lists

US Toxic Substances Control Act (TSCA) - Chemical Substance Inventory

isocyclemone E is found on the following regulatory lists

US Toxic Substances Control Act (TSCA) - Chemical Substance Inventory

SECTION 16 Other information

Other information

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

End of SDS